Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLBS201 in CKD and T2DM
NCT04990427Phase 1Completed
- Sponsor
- Lisata Therapeutics
- Start
- Jan 2022
- Primary completion
- Jan 2023
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CLBS201 in diabetic kidney disease (DKD), sponsored by Lisata Therapeutics. Primary endpoint: Serious Adverse Events at 6 months. Started Jan 2022; status: completed.
02
Drugs
CLBS201
03
Conditions
diabetic kidney disease (DKD)
Beyond the preview
Go deeper on NCT04990427.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04990427.